Table 3.
Absorbed doses in MPC tumor allografts and animal survival after treatment with lutetium‑177- and copper‑67-labeled TATE variants
| TATE variant | RN | A m | DT, Tumor | PFS # | OS † | Animals |
|---|---|---|---|---|---|---|
| [MBq/nmol] | [Gy] | [days] | [days] | n (per exp.) | ||
| Control/vehicle | - | - | - | 3.40 | 15.2 | 8 (3, 3, 2) |
| DOTA | 177Lu | 39.6 ± 0.09 | 41.1 ± 3.65 | 18.7 | 28.4 | 5 (5) |
| 22.6 ± 1.42 | 22.0 ± 1.11 | 11.3 | 22.7 | 6 (3, 3) | ||
| NODAGA | 67Cu | 40.3 ± 0.76 | 9.51 ± 0.95 | 8.06 | 21.0 | 6 (4, 2) |
| 24.6 ± 0.67 | 7.82 ± 0.79 | 7.42 | 16.9 | 5 (3, 2) | ||
| NODAGA-cLAB4 | 67Cu | 41.5 ± 0.56 | 40.2 ± 3.09 | 16.6 | 27.3 | 6 (3, 3) |
| 21.5 ± 0.54 | 34.6 ± 2.73 | 13.9 | 25.2 | 5 (2, 1, 2) |
Each animal received an initial activity dose of 50 MBq; (Am) molar activity at treatment start; (DT, Tumor) mean absorbed dose in tumors; (n) number of animals per group and per independent experiment; (OS) overall survival defined as < 10‑fold change in tumor volume and (PFS) progression-free survival defined as < 2‑fold change in tumor volume compared to treatment start; (RN) radionuclide; Am, ID, and DT presented as means ± standard error, PFS and OS presented as medians; Pearson correlation coefficient (rp) and significance of linear relationships with DT: † r = 0.96, p < 0.01, # r = 0.98, p < 0.001